Cargando…

Advances in Antibody-Drug Conjugates in the Treatment of HER2-Positive Breast Cancer

Although targeted drugs improved the therapeutic effect of HER2-positive breast cancer, the long-term prognosis was still poor. In this regard, the research and development of antibody-drug conjugates (ADCs) came into being and made a lot of progress. ADCs had the characteristics of both chemotherap...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Yongchao, Wang, Jin, Liao, Dongying, Zhang, Dou, Li, Xiaojiang, Jia, Yingjie, Kong, Fanming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9747846/
https://www.ncbi.nlm.nih.gov/pubmed/36532256
http://dx.doi.org/10.2147/BCTT.S384830
_version_ 1784849695132090368
author Yu, Yongchao
Wang, Jin
Liao, Dongying
Zhang, Dou
Li, Xiaojiang
Jia, Yingjie
Kong, Fanming
author_facet Yu, Yongchao
Wang, Jin
Liao, Dongying
Zhang, Dou
Li, Xiaojiang
Jia, Yingjie
Kong, Fanming
author_sort Yu, Yongchao
collection PubMed
description Although targeted drugs improved the therapeutic effect of HER2-positive breast cancer, the long-term prognosis was still poor. In this regard, the research and development of antibody-drug conjugates (ADCs) came into being and made a lot of progress. ADCs had the characteristics of both chemotherapeutic agents and targeted agents by combining chemotherapeutic agents and targeted agents through a linker. It not only had a strong anti-tumor effect on HER2-positive breast cancer, but also had certain anti-tumor effects on HER2-low and even HER2-negative patients. In addition, the clinical researches of ADCs combined with immune checkpoint inhibitors (ICIs) therapy had also made a great breakthrough. This review aimed to summarize the clinical progress of ADCs, in particular the two drugs approved by the US Food and Drug Administration (FDA) for HER2-positive metastatic breast cancer as well as to summarize the current status of ADCs in combination with ICIs.
format Online
Article
Text
id pubmed-9747846
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-97478462022-12-15 Advances in Antibody-Drug Conjugates in the Treatment of HER2-Positive Breast Cancer Yu, Yongchao Wang, Jin Liao, Dongying Zhang, Dou Li, Xiaojiang Jia, Yingjie Kong, Fanming Breast Cancer (Dove Med Press) Review Although targeted drugs improved the therapeutic effect of HER2-positive breast cancer, the long-term prognosis was still poor. In this regard, the research and development of antibody-drug conjugates (ADCs) came into being and made a lot of progress. ADCs had the characteristics of both chemotherapeutic agents and targeted agents by combining chemotherapeutic agents and targeted agents through a linker. It not only had a strong anti-tumor effect on HER2-positive breast cancer, but also had certain anti-tumor effects on HER2-low and even HER2-negative patients. In addition, the clinical researches of ADCs combined with immune checkpoint inhibitors (ICIs) therapy had also made a great breakthrough. This review aimed to summarize the clinical progress of ADCs, in particular the two drugs approved by the US Food and Drug Administration (FDA) for HER2-positive metastatic breast cancer as well as to summarize the current status of ADCs in combination with ICIs. Dove 2022-12-09 /pmc/articles/PMC9747846/ /pubmed/36532256 http://dx.doi.org/10.2147/BCTT.S384830 Text en © 2022 Yu et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Yu, Yongchao
Wang, Jin
Liao, Dongying
Zhang, Dou
Li, Xiaojiang
Jia, Yingjie
Kong, Fanming
Advances in Antibody-Drug Conjugates in the Treatment of HER2-Positive Breast Cancer
title Advances in Antibody-Drug Conjugates in the Treatment of HER2-Positive Breast Cancer
title_full Advances in Antibody-Drug Conjugates in the Treatment of HER2-Positive Breast Cancer
title_fullStr Advances in Antibody-Drug Conjugates in the Treatment of HER2-Positive Breast Cancer
title_full_unstemmed Advances in Antibody-Drug Conjugates in the Treatment of HER2-Positive Breast Cancer
title_short Advances in Antibody-Drug Conjugates in the Treatment of HER2-Positive Breast Cancer
title_sort advances in antibody-drug conjugates in the treatment of her2-positive breast cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9747846/
https://www.ncbi.nlm.nih.gov/pubmed/36532256
http://dx.doi.org/10.2147/BCTT.S384830
work_keys_str_mv AT yuyongchao advancesinantibodydrugconjugatesinthetreatmentofher2positivebreastcancer
AT wangjin advancesinantibodydrugconjugatesinthetreatmentofher2positivebreastcancer
AT liaodongying advancesinantibodydrugconjugatesinthetreatmentofher2positivebreastcancer
AT zhangdou advancesinantibodydrugconjugatesinthetreatmentofher2positivebreastcancer
AT lixiaojiang advancesinantibodydrugconjugatesinthetreatmentofher2positivebreastcancer
AT jiayingjie advancesinantibodydrugconjugatesinthetreatmentofher2positivebreastcancer
AT kongfanming advancesinantibodydrugconjugatesinthetreatmentofher2positivebreastcancer